Transactions

Transactions

  • Cowen is pleased to announce that Mission Treatment Services, Inc., a leading operator of clinics that provide opioid use disorder treatment in the form of outpatient medication-assisted treatment MAT, has been acquired by Acadia Healthcare Company.
  • Avedro is a commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision.
  • Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology
  • Monocle Acquisition Corporation, a Delaware corporation, is a blank check company newly formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses.
  • Cowen is pleased to announce that Great Hill Partners, LLC., a leading growth-oriented private equity firm, announced that it has completed the sale of Zoom Information, Inc., a leading B2B data provider, to DiscoverOrg, LLC
  • Catalyst is a leading provider of eDiscovery solutions for corporate legal departments and top law firms.
  • Andina Acquisition Corp. III is a Cayman Islands exempted company incorporated as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
  • Cowen is pleased to announce that North American Rescue, a portfolio company of Blue Wolf Capital Partners LLC, has entered into a definitive agreement to be acquired by Henry Schein, Inc.
  • Cowen provided a fairness opinion to Tilrays board of directors in connection with the transaction.
  • Pamplona has acquired a controlling interest in Latham Pool Products, Inc. from Wynnchurch Capital, which will remain a significant investor in the Company.
  • The Company intends to use the net proceeds to support expansion initiatives future acquisitions and general corporate purposes, including working capital requirements.
  • Stemline intends to use the net proceeds from this offering for commercial activities of ELZONRIS (formerly SL 401) including clinical trials for additional indications including CMML, MF and other diseases, clinical development of SL 801, SL 701 and potentially SL-901, research and development activities, potential acquisitions and in-licensing and other general corporate purposes.
1 2 3 4 ...91 Next